Kidney patients may not need long blood thinners after stents
NCT ID NCT04708587
First seen Jan 18, 2026 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This study compares taking two blood thinners (aspirin plus clopidogrel or prasugrel) for less than 3 months versus at least 6 months after a heart stent procedure in people with advanced chronic kidney disease. Researchers want to see if a shorter course reduces bleeding without increasing heart attacks or strokes. About 900 adults with severe kidney disease are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aspirin plus clopidogrel or prasugrel
What this could lead to
If it works, this could show that a shorter course of dual antiplatelet therapy is safer and just as effective for people with advanced kidney disease after stenting.
What could go wrong
This is a mid-sized trial, not a large Phase 3 study, so results may not apply to all patients. There is always a risk of bleeding or clotting events regardless of duration.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.